KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Non-Current Liabilities: 2024-2025

Historic Other Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 2 years, with Sep 2025 value amounting to $1.0 million.

  • Recursion Pharmaceuticals' Other Non-Current Liabilities fell 65.69% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 65.69%. This contributed to the annual value of $4.7 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Other Non-Current Liabilities of $1.0 million as of Q3 2025, which was down 34.25% from $1.6 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $4.8 million during Q1 2025, with a 5-year trough of $1.0 million in Q3 2025.
  • For the 2-year period, Recursion Pharmaceuticals' Other Non-Current Liabilities averaged around $3.0 million, with its median value being $3.0 million (2024).
  • Data for Recursion Pharmaceuticals' Other Non-Current Liabilities shows a maximum YoY slumped of 65.69% (in 2025) over the last 5 years.
  • Recursion Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $4.7 million in 2024, then tumbled by 65.69% to $1.0 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.0 million for Q3 2025, versus $1.6 million for Q2 2025 and $4.8 million for Q1 2025.